Eli Lilly: Q4 EPS beats estimates
(CercleFinance.com) - Eli Lilly has reported adjusted EPS that is up 31% at 1.
73 dollar, over twenty cents above the consensus, for revenues that are up 8% at 6.11 billion dollars, of which 46% came from products that have been launched since 2014.
The Indianapolis based pharmaceutical laboratory thus saw its FY 2019 adjusted EPS increase by 11% to 6.04 dollars, exceeding its target range of 5.75-5.85 dollars, with the group confirming its Fy 2020 forecast for adjusted EPS of between 6.70-6.80 dollars.
David A. Ricks, Lilly's chairman and CEO. "We look forward to continuing this progress in 2020, as our scientists work to expand our portfolio of innovative medicines to offer new treatment options for patients in the areas of diabetes, oncology, immunology, and neuroscience."
Copyright (c) 2020 CercleFinance.com. All rights reserved.